Starpharma (ASX:SPL) see Okamoto licence Vivagel condoms in Asian countries

Company News

by Rachael Jones

Starpharma (ASX:SPL) today announced that following the successful launch of the VivaGel antiviral condom by Okamoto Industries in Japan, they are now seeking to expand its licence territory in Japan.

As a result, Starpharma has granted Okamoto marketing rights to a further 11 countries in Asia which include South Korea, Indonesia, Malaysia, Thailand, Singapore and the non-government China market.

Okamoto holds strong condom market positions in the region, with a number 1 or 2 ranking in several of the relevant Asian countries.

They have a revenue of approximately US$1 billion with more than 2,600 employees and is Japan’s leading marketer of condoms.

Shares in Starpharma (ASX:SPL) are trading 0.5 per cent lower at $1.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.